MRSN's free cash flow for Q4 2023 was $-32.35M. For the 2023 fiscal year, MRSN's free cash flow was decreased by $-119.49M and operating cash flow was $-31.96M. See a summary of the company’s cash flow.

Cash Flow	TTM	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Operating Cash Flow	$ -168.88M	$ -168.88M	$ -49.36M	$ -139.99M	$ -74.70M	$ -67.74M
Investing Cash Flow	$ 119.88M	$ 119.88M	$ -152.72M	$ -648.00K	$ 37.03M	$ -27.29M
Financing Cash Flow	$ 94.65M	$ 94.67M	$ 153.02M	$ 63.65M	$ 230.41M	$ 97.70M
Cash Flow From Discontinued Operation	-	-	-	-	-	-
Other Cash Adjustment Inside Changein Cash	-	-	-	-	-	-
End Cash Position	$ 556.22M	$ 129.36M	$ 129.36M	$ 178.43M	$ 255.41M	$ 62.67M
Income Tax Paid Supplemental Data	-	-	-	-	-	-
Interest Paid Supplemental Data	$ 3.38M	$ 3.38M	$ 2.46M	$ 429.00K	$ 234.00K	$ 132.00K
Issuance Of Capital Stock	-	-	-	-	$ 227.03M	$ 92.16M
Issuance Of Debt	$ -112.00K	$ -262.00K	$ -272.00K	$ -5.70M	-	$ 4.96M
Repayment Of Debt	$ -112.00K	$ -262.00K	$ -272.00K	$ -5.70M	$ -313.00K	$ -87.00K
Free Cash Flow	$ -171.05M	$ -171.05M	$ -51.56M	$ -140.64M	$ -75.17M	$ -68.35M
Domestic Sales	-	-	-	-	-	-
Foreign Sales	-	-	-	-	-	-

Currency in USD

Mersana Therapeutics Cash Flow

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing